findmyKOL
Clinical trialNCT06958796RecruitingPhase 4Interventional

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

SponsorCamille N. Kotton, MDEnrollment80CytomegalovirusKidney Transplant; ComplicationsLiver Transplant ComplicationsOrgan TransplantSimultaneous Liver-Kidney Transplantation; Complications
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Massachusetts General Hospital

    Boston, Massachusetts, United States

    Camille Kotton, MD
    Recruiting
  • University of Texas Southwestern

    Dallas, Texas, United States

    David Wojciechowski, DO
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
27 Nov 2025
Primary completion
30 Dec 2027
Completion
31 May 2028
Last update posted
22 Dec 2025
Registered enrollment
80
Registry id
NCT06958796
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.